Catalyst Event
Amgen Inc (AMGN) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
4/28/2026, 12:00:00 AM
On April 28, 2026, the U.S. FDA's CDER proposed to withdraw the approval for Amgen's drug Tavneos due to effectiveness and safety concerns. High importance is estimated as drug withdrawals significantly impact revenue and reputation.
Korean Translation
2026년 4월 28일, 미국 FDA CDER이 효능 및 안전성 우려를 이유로 타브네오스(Tavneos)의 승인 철회를 제안함. 품목 허가 취소는 매출 및 기업 신뢰도에 중대한 영향을 미치므로 높은 중요도로 예상함.
Related Recent Events
Lululemon Athletica Inc (LULU) · Earnings Release
Lululemon's Q1 2026 earnings release is scheduled for June 4, 2026, with analysts forecasting weak results following previous guidance. Earnings releases typically result in a >5% price impact, justifying a Medium importance, scheduled.
6/4/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Earnings Release
Medium importance is estimated due to the historical impact of quarterly earnings on stock volatility. Q1 2026 earnings release is scheduled.
5/27/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
Novo Nordisk is scheduled to announce its first quarter 2026 financial results. Low importance as it is a routine earnings call, scheduled.
5/6/2026, 12:00:00 AM
Life Time Group Holdings Inc (LTH) · Earnings Release
Life Time is scheduled to release its Q1 2026 financial results before market open on May 5, 2026. Importance is Medium as earnings releases typically result in price movements exceeding 5%, scheduled.
5/5/2026, 12:00:00 AM
Amgen Inc (AMGN) · Earnings Release
Amgen is scheduled to report its first quarter 2026 financial results after the market close on April 30, 2026, followed by a conference call with management, scheduled. High importance is estimated due to typical volatility surrounding earnings releases.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Eli Lilly is scheduled to announce its first-quarter 2026 financial results on April 30, 2026. This is a recurring event with high potential for stock price impact (analysts estimate ≥10%) based on revenue, earnings per share, and future guidance. scheduled
4/30/2026, 12:00:00 AM